Financial Performance - AngioDynamics' total Med Device revenue grew by 62% pro forma in Q4 2025[5,9] - AngioDynamics' total Med Tech revenue grew by 220% pro forma in Q4 2025[5,9] - AngioDynamics reported pro forma Adjusted EBITDA of $34 million in Q4 2025, a $19 million improvement from Q4 FY24[5] - AngioDynamics ended the quarter with $559 million in cash and cash equivalents, up from $448 million at Feb 28, 2025[5] - AngioDynamics' total Med Tech revenue grew by 195% pro forma for FY 2025[12] - AngioDynamics' total Med Device revenue grew by 08% pro forma for FY 2025[12] Product Line Performance - Auryon sales reached $156 million in Q4 2025, a 197% year-over-year growth[16] - Total Mechanical Thrombectomy sales were $113 million in Q4 2025, a 447% year-over-year growth[5,20] - NanoKnife disposables sales grew by 55% in Q4 2025, while total NanoKnife sales decreased by 25%[5,25] Future Outlook - AngioDynamics projects full-year net sales between $305 million and $310 million for Fiscal Year 2026[27]

Financial Performance - Assets Under Management (AUM) reached $12.5 trillion as of June 30, 2025[2] - Q2 2025 Base Fees and Securities Lending Revenue totaled $4.5 billion[2] - Q2 2025 Operating Income, as adjusted, was $2.099 billion[8] - Q2 2025 Net Income, as adjusted, was $1.883 billion[9] - Q2 2025 EPS, as adjusted, reached $12.05[9] Net Flows - Total BlackRock Retail Long-term net flows for Q2 2025 were $82 billion[5] - Institutional Long-term net flows for Q2 2025 were $(48) billion[5] - ETFs Long-term net flows for Q2 2025 were $85 billion[5] Revenue Breakdown - Base fees constitute 79% of the quarterly revenue[22] - Tech services & subscription revenue accounts for 9% of the quarterly revenue[22] - Securities lending revenue represents 2% of the quarterly revenue[22] Expense Breakdown - Employee compensation and benefits make up 50% of the quarterly expenses, as adjusted[33] - Sales, asset & account expenses account for 32% of the quarterly expenses, as adjusted[33] - General & administration expenses represent 18% of the quarterly expenses, as adjusted[33] Capital Management - Share repurchases for Q2 2025 amounted to $375 million[14] - Dividends per share for Q2 2025 were $5.21[16]

Financial Performance - The company's Q3 2025 revenue reached $20.4 million, a 10% increase compared to $18.5 million in Q3 2024[4] - Adjusted EBITDA margin for Q3 2025 was 37%, up from 30% in Q3 2024[4] - Diluted EPS for Q3 2025 was $(3.35), while adjusted diluted EPS was $0.45[4] - Trailing Twelve Months (TTM) revenue for Q3 2025 was $80.4 million, a 20% increase from $67.0 million in Q3 2024[5] - The company is guiding for total revenue between $76 million and $80 million for fiscal year 2025, representing a growth of 9% to 14%[38] Software Segment - Overall software revenue grew by 6% in Q3 2025 and 16% for TTM[7] - Pro-ficiencyTM software revenue contribution was below expectations[7] - TTM revenue for Pro-ficiencyTM was $4.4 million[7] Services Segment - Overall services revenue grew by 17% in Q3 2025 and 27% for TTM[10] - Total backlog for services was $20.7 million, with over 91% expected to be converted to revenue within 12 months[10] - TTM revenue for Med Comm services was $7.3 million[10]

Financial Performance - Second quarter net sales increased by 8.6%, primarily driven by improved customer contract signings over the past six quarters[6] - Earnings per share (EPS) for the second quarter improved 12.7% to $0.29, compared to $0.25 in the second quarter of the previous year[12] - The operating margin improved to 21.0% in the second quarter, up from 20.2% in the second quarter of the previous year[12] - Gross profit margin increased to 45.3% from 45.1% in the second quarter of the previous year, reflecting favorable price/cost dynamics and improved fastener sales margins[28] - Operating cash flow (OCF) for the second quarter was $278.6 million, representing 84.4% of net income[31] Customer Site Performance - The number of customer sites with sales over $10,000 per month grew by 6.7%, led by Onsite-like locations which increased by 12.4%[6] - Sites with sales over $10,000 per month accounted for 81.4% of net sales in the second quarter, up from 79.2% in the second quarter of the previous year[6] - Total manufacturing customer sites were 43,138 with sales of $1,575.4 million, while total non-manufacturing customer sites were 58,302 with sales of $504.9 million[7] Digital Footprint and Technology - Daily sales through eBusiness rose 13.5% in the second quarter[18] - Activity through the company's FMI (Fastenal Managed Inventory) technology platform represented 44.1% of sales in the second quarter, compared to 41.8% and 39.8% in the second quarter of the previous year and the year before, respectively[17] - Sales through the digital footprint (FMI technology plus non-FMI-related eBusiness) accounted for 61.0% of total sales in the second quarter, versus 59.4% and 55.3% in the second quarter of the previous year and the year before, respectively[18]

2Q25 Preliminary Results - Revenue (FTE) reached $1,954 million, a 7.6% year-over-year increase[9] - EPS was $0.34, up 13.3% year-over-year[9] - Average loans amounted to $133.2 billion, reflecting a 7.9% increase[9] - Average deposits totaled $163.4 billion, showing a 6.4% increase[9] - Tangible book value per share (TBVPS) stood at $9.13, a 15.7% increase[9] Strategic Partnership with Veritex - Huntington is partnering with Veritex to accelerate organic growth in Texas[9, 10] - The transaction value is $1.9 billion[27] - Veritex has $12.6 billion in assets[21] - Veritex has $9 billion in loans and $11 billion in deposits[21, 24] - Veritex has 31 branches located in DFW & Houston[21]

Transaction Overview - BD will separate its Biosciences and Diagnostic Solutions business to BD shareholders and simultaneously merge SpinCo with a wholly owned subsidiary of Waters in a tax-efficient Reverse Morris Trust transaction valued at approximately $17.5 billion[65] - Expected pro forma ownership of 60.8% for Waters shareholders and 39.2% for BD shareholders[65] - BD to receive approximately $4 billion cash distribution via proceeds of SpinCo debt[65] - The transaction is expected to close around the end of the first quarter of calendar year 2026[65] Financial Highlights - Pro forma revenue for CY 2025E is approximately $6.5 billion[18] - Adjusted EBITDA for CY 2025E is approximately $2.0 billion[18] - R&D spending is approximately 10% of sales[18] - The transaction is expected to be EPS accretive in Year 1[36] - Expected revenue synergies of approximately $290 million by Year 5, with an EBITDA impact of $145 million[33, 61] - Expected cost synergies of approximately $200 million by Year 3[33, 61] - Approximately $345 million in total annualized adjusted EBITDA synergies are expected by Year 5[36, 61] Growth and Stability - The combined company will have a total addressable market (TAM) of approximately $40 billion with 5-7% market growth[19, 22] - Over 70% of revenue is annually recurring[19, 30] - Over 50% of instruments are replaced every 5-10 years[19, 30] - Expected sales growth in the near-to-mid-term is MSD-HSD (Mid-Single-Digit to High-Single-Digit)[33] - Adjusted operating margin expansion of approximately 500 bps is expected by 2030[33]

Transaction Overview - BD will separate its Biosciences and Diagnostic Solutions business to BD shareholders and simultaneously merge SpinCo with a wholly owned subsidiary of Waters in a tax-efficient Reverse Morris Trust transaction valued at approximately $17.5 billion[65] - Expected pro forma ownership of 60.8% for Waters shareholders and 39.2% for BD shareholders[65] - BD to receive approximately $4 billion cash distribution via proceeds of SpinCo debt[65] - The transaction is expected to close around the end of the first quarter of calendar year 2026[65] Financial Highlights - Pro forma revenue for CY 2025E is approximately $6.5 billion[18] - Adjusted EBITDA for CY 2025E is approximately $2.0 billion[18] - R&D spending is approximately 10% of sales[18] - The transaction is expected to be EPS accretive in Year 1[36] - Expected revenue synergies of approximately $290 million by Year 5, with an EBITDA impact of $145 million[33, 61] - Expected cost synergies of approximately $200 million by Year 3[33, 61] - Approximately $345 million in total annualized adjusted EBITDA synergies are expected by Year 5[36, 61] Growth and Stability - The combined company will have a total addressable market (TAM) of approximately $40 billion with 5-7% market growth[19, 22] - Over 70% of revenue is annually recurring[19, 30] - Over 50% of instruments are replaced every 5-10 years[19, 30] - Expected sales growth in the near-to-mid-term is MSD-HSD (Mid-Single-Digit to High-Single-Digit)[33] - Adjusted operating margin expansion of approximately 500 bps is expected by 2030[33]

Company Overview and Mission - Sezzle's mission is to financially empower the next generation by enabling merchants to offer customer-friendly credit alternatives [11, 12, 13] - The company aims to provide flexible, reliable, transparent, and secure services to both merchants and consumers [14] - Sezzle highlights its commitment to trust, financial freedom, technology, and the future [16, 17, 18, 19] - Sezzle is transitioning to a Public Benefit Corporation, focusing on purpose-driven actions and benefits for all stakeholders [20] Growth and Market Opportunity - Sezzle experienced triple-digit year-over-year growth in revenue, consumers, and merchants in 2018, 2019, and Q1 2020 [24] - The company operates in large retail markets: US (over $5.4 trillion), Canada ($461.1 billion), and Australia ($215 billion) [25] - Sezzle has over 1.3 million active consumers and over 14.9K active merchants [28] 2019 Performance Highlights - Sezzle completed its Initial Public Offering (IPO) at A$1.22 per CDI on July 29, 2019 [30] - The company secured a $100 million credit facility in November 2019, maturing in May 2022 [30] - There was significant growth in 2019, including a 775% increase in merchant fees, a 685% increase in merchant sales, and a 489% increase in active consumers [30] COVID-19 Impact and Response - Sezzle implemented a mandatory work-from-home policy and suspended business travel for employees [76] - The company expanded fee forgiveness and payment flexibility programs for consumers [77] - Sezzle highlights the potential positive impact of the US government's stimulus measures on its stakeholders [81] 2020 Momentum - In May, Underlying Merchant Sales (UMS) surged 321% year-over-year [93] - Active Customers rose 326% year-over-year in May [93]

Financial Performance (LTM 1Q 2016) - Westlake Chemical Corporation reported Net Sales of $4335 million[6] - The company's EBITDA was $1217 million[6] - Net Income attributable to Westlake was $623 million[6] - Olefins contributed $822 million to EBITDA, representing 67% of the total[6] - Vinyls contributed $410 million to EBITDA, representing 33% of the total[6] Strategic Advantages and Growth Drivers - The company leverages a strong ethane and other NGL advantage due to fundamental structural advances in supply[13] - Significant product integration allows the company to capture the full value chain[13] - Westlake is well-positioned for continued profitable growth due to its ongoing financial strength and flexibility[13] - Westlake has one of the highest LDPE product mix percentages in North America[30] - Global PVC demand is growing, supporting exports[45]

Financial Performance - Westlake Chemical Corporation reported net sales of $6.936 billion and EBITDA of $1.291 billion [4] - Net income attributable to Westlake Chemical Corporation was $456 million [4] - Olefins contributed $750 million to EBITDA, representing 53% of the total, while Vinyls contributed $658 million, accounting for 47% [4] Strategic Acquisitions and Synergies - The acquisition of Axiall has created a diverse, vertically-integrated chemicals leader, enhancing margin stability and growth opportunities [7] - Westlake expects to realize $120 million in synergy savings and cost reductions in 2017, with a total of $200 million expected by 2018 [7] Ethylene and Feedstock Advantages - Westlake has a short position in ethylene, providing cost advantages in the coming years due to its all-ethane feedstock capability [11, 12] - The company's ethylene plants are fully capable of using ethane and have some NGL flexibility, with the European business (Vinnolit) providing further feedstock diversification [22] Polyethylene Product Mix - Westlake has an advantaged polyethylene product mix, with LDPE accounting for 58% and LLDPE for 42% of its capacity [24] - The company focuses on LDPE, which has a higher average margin advantage compared to other PE grades [24] PVC and Global Presence - The Axiall acquisition has given Westlake a global PVC presence with facilities in North America, Europe, and Asia [36] - Westlake/Vinnolit is a leading specialty PVC producer with a global capacity of approximately 4,000 KMT in 2016 [48]